<DOC>
	<DOCNO>NCT01080261</DOCNO>
	<brief_summary>A non-randomized , small vessel ( SV ) trial approximately 15 site Japan enroll 60 patient de novo lesion ≤28 mm length ( visual estimate ) native coronary artery ≥2.25 mm &lt; 2.50 mm diameter ( visual estimate ) . Approximately thirty patient randomly assign angiographic subset also undergo angiographic assessment 12-month clinical follow-up .</brief_summary>
	<brief_title>PROMUS Element Japan Small Vessel Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient must least 20 year age Patient understand study requirement treatment procedure provide write informed consent studyspecific test procedure perform Patient eligible percutaneous coronary intervention ( PCI ) regard target lesion Patient consider suitable PCI follow criterion meet . Evidence ischemia document stress electrocardiogram ( ECG ) and/or diagnostic imaging test . Target vessel supply blood relatively large area myocardium . Target lesion possible culprit angina . Target vessel potential collateral source major vessel Patient document stable angina pectoris document silent ischemia ; unstable angina pectoris Patient acceptable candidate coronary artery bypass grafting ( CABG ) Patient leave ventricular ejection fraction ( LVEF ) ≥30 % measure within 30 day prior enrollment Patient willing comply protocolrequired followup evaluation Patient clinical symptom and/or ECG change consistent acute myocardial infarction ( MI ) Patient know diagnosis recent MI ( i.e. , within 72 hour prior index procedure ) elevate enzymes time index procedure follow . Patients exclude follow criterion meet time index procedure . If creatine kinasemyoglobin band ( CKMB ) &gt; 2× upper limit normal ( ULN ) , patient exclude regardless CK Total . If CK MB 1 2× ULN , patient exclude CK Total &gt; 2× ULN . If CK Total/CK MB use Troponin , patient exclude follow criterion meet time index procedure . Troponin &gt; 1× ULN least one follow . Patient ischemic symptom ECG change indicative ongoing ischemia ( e.g. , &gt; 1 mm ST segment elevation depression consecutive lead new left bundle branch block [ LBBB ] ) ; Development pathological Q wave ECG ; Imaging evidence new loss viable myocardium new regional wall motion abnormality . Note : For patient unstable angina patient recent MI , CK Total/CK MB ( Troponin CK Total/CK MB use ) must document prior enrol patient . Patient receive organ transplant wait list organ transplant Patient receiving schedule receive chemotherapy within 30 day index procedure Patient receive oral intravenous immunosuppressive therapy ( inhaled steroid exclude ) know lifelimiting immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , include diabetes mellitus ) Patient receive chronic ( ≥72 hour ) anticoagulation therapy ( e.g. , heparin , warfarin ) indication acute coronary syndrome Patient platelet count &lt; 100,000 cells/mm^3 &gt; 700,000 cells/mm^3 Patient white blood cell ( WBC ) count &lt; 3,000 cells/mm^3 Patient document suspect liver disease , include laboratory evidence hepatitis Patient dialysis know renal insufficiency ( i.e. , Creatinine &gt; 2.0 mg/dl &gt; 150 μmol/L ) Patient history bleed diathesis coagulopathy refuse blood transfusion Patient cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month , permanent neurologic defect may cause noncompliance protocol Target vessel side branch treat type PCI ( e.g. , balloon angioplasty , stent , cut balloon , atherectomy ) within 12 month prior index procedure ( exclude PCI nontarget lesion within target vessel treat index procedure ( Refer Multiple Interventions During Index Procedure ) ) Target vessel treat within 10 mm proximal distal target lesion ( visual estimate ) type PCI ( e.g. , balloon angioplasty , stent , cut balloon , atherectomy ) time prior index procedure Nontarget vessel side branch treat type PCI ( e.g. , balloon angioplasty , stent , cut balloon , atherectomy ) within 24 hour prior index procedure Planned actual target vessel treatment unapproved device , directional rotational coronary atherectomy , laser , cut balloon , transluminal extraction catheter immediately prior stent placement Planned PCI CABG index procedure Patient previously treat time coronary intravascular brachytherapy Patient know allergy study stent system protocolrequired concomitant medication ( e.g. , stainless steel , platinum , chromium , nickel , tungsten , acrylic , fluoropolymers , everolimus , thienopyridines , aspirin , contrast ) adequately premedicated Patient active peptic ulcer active gastrointestinal ( GI ) bleed Patient one following . Other serious medical illness ( e.g. , cancer , congestive heart failure ) may reduce life expectancy le 24 month Current problem substance abuse ( e.g. , alcohol , cocaine , heroin , etc . ) Planned procedure may cause noncompliance protocol confound data interpretation Patient participate another investigational drug device clinical trial reach primary endpoint Patient intend participate another investigational drug device clinical trial within 12 month index procedure Patient know intention procreate within 12 month index procedure ( Women childbearing potential sexually active must agree use reliable method contraception time screen 12 month index procedure . ) Patient woman pregnant nursing ( A pregnancy test must perform within 7 day prior index procedure woman childbearing potential . ) Patient 1 target lesion 1 nontarget lesion , treat index procedure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Coronary Artery Disease</keyword>
</DOC>